Type 2 diabetes (T2D) is characterized by insulin resistance and progressive beta-cell dysfunction. Diagnosis: fasting glucose ≥126 mg/dL, A1C ≥6.5%, or two-hour OGTT ≥200 mg/dL. GLP-1 RAs are first- or second-line therapy depending on comorbidities. ADA 2026 guidelines recommend GLP-1 RA early when CV or weight comorbidities are present.
Also known as
T2Dtype 2 diabetes mellitus
Related terms
- A1C
- Average blood sugar over the past 2-3 months. Healthy: <5.7%. Pre-diabetes: 5.7-6.4%. Diabetes: ≥6.5%.
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- SUSTAIN 6
- CV outcomes trial of Ozempic (semaglutide) in T2D. 26% MACE reduction.